Enlivex Receives Notice of Allowance for Japanese Patent Application Covering Allocetra Derived from Pooled Donor Cells
Enlivex Therapeutics Ltd. (Nasdaq: ENLV) announced the issuance of a Notice of Allowance from the Japanese Patent Office for patent application number 2020-198242. This patent will grant intellectual property protection for the use of pooled donor cells in Allocetra™, extending protection until at least 2037. Enlivex aims to bolster its global IP strategy to enhance the commercial potential of Allocetra™, a reprogramming immunotherapy targeting diseases like sepsis and solid tumors. The patent is expected to be issued in Q2 2023, emphasizing Enlivex’s commitment to addressing unmet medical needs.
- Notice of Allowance from the Japanese Patent Office for patent number 2020-198242.
- Potential for extended IP protection for Allocetra™ through at least 2037.
- Demonstrates commitment to global IP strategy enhancing commercial opportunities.
- None.
Nes-Ziona, Israel, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis and solid tumors, today announced that the Japanese Patent Office issued a Notice of Allowance for patent application number 2020-198242. Once issued, the resulting patent will provide Enlivex with added intellectual property (IP) protection through at least 2037, with claims covering the use of pooled donor cells as source materials for Allocetra™. The Company expects that this new patent will be issued in Japan by the second quarter of 2023.
Oren Hershkovitz, Ph.D., Chief Executive Officer of Enlivex, commented, “this Notice of Allowance demonstrates our commitment to protecting Allocetra’s™ commercial opportunities in key geographies around the world. It also highlights the successful execution of our global IP strategy. Going forward, we will continue to pursue multiple layers of patent protection in key global markets as we work to develop Allocetra™ as a next generation cell therapy for life threatening disease with unmet medical needs.”
Enlivex is developing Allocetra™ as a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, Allocetra™ has the potential to provide a novel immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as "unmet medical needs", as a stand-alone therapy or in combination with leading therapeutic agents.
ABOUT ENLIVEX
Enlivex is a clinical stage macrophage reprogramming immunotherapy company developing Allocetra™, a universal off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Resetting non-homeostatic macrophages into their homeostatic state is critical for immune system rebalancing and resolution of life-threatening conditions. For more information, visit http://www.enlivex.com.
Safe Harbor Statement: This press release contains forward-looking statements, which may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “would”, “could,” “intends,” “estimates,” “suggests,” “has the potential to” and other words of similar meaning, including statements regarding expected cash balances, market opportunities for the results of current clinical studies and preclinical experiments, the effectiveness of, and market opportunities for, ALLOCETRATM programs. All such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect Enlivex’s business and prospects, including the risks that Enlivex may not succeed in generating any revenues or developing any commercial products; that the products in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any activity; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. The results of clinical trials in humans may produce results that differ significantly from the results of clinical and other trials in animals. The results of early-stage trials may differ significantly from the results of more developed, later-stage trials. The development of any products using the ALLOCETRATM product line could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties. In addition to the risk factors described above, investors should consider the economic, competitive, governmental, technological and other factors discussed in Enlivex’s filings with the Securities and Exchange Commission, including in the Company’s most recent Annual Report on Form 20-F filed with the Securities and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements, except as required under applicable law.
ENLIVEX CONTACT
Shachar Shlosberger, CFO
Enlivex Therapeutics, Ltd.
shachar@enlivexpharm.com
INVESTOR RELATIONS CONTACT
Eric Ribner
LifeSci Advisors
eric@lifesciadvisors.com
FAQ
What recent patent news did Enlivex Therapeutics (ENLV) announce?
How long will the new patent protect Enlivex's Allocetra™?
What is the significance of the patent announcement for ENLV investors?
What disease indications does Allocetra™ target?
